Movement Alert｜Pharmaron Rises 5.59% in Regular Trading, H1 Revenue Forecast Up 16%-19% YoY with New Orders Surging Over 30%

Market Focus07-14

On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on July 13.

Pharmaron expects H1 revenue of RMB 7.47 billion to RMB 7.66 billion, representing 16%-19% YoY growth. Attributable net profit is forecast at RMB 729 million to RMB 772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884 million to RMB 922 million, up 17%-22% YoY. The company attributed the growth to deepening global expansion, with newly signed orders rising over 30% YoY, including small-molecule CDMO orders surging over 50%. Based on mid-range estimates, Q2 revenue grew 19.38% YoY with profitability accelerating sequentially, as Q2 net profit is projected at RMB 394-436 million versus Q1's RMB 335 million, implying 17%-30% QoQ growth.

Notably, Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovering global biopharma funding and strong outsourcing demand.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152859766?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152859766","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 5.59% in Regular Trading, H1 Revenue Forecast Up 16%-19% YoY with New Orders Surging Over 30%","media":"Market Focus","content":"<p><p>On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on July 13.</p><p>Pharmaron expects H1 revenue of RMB 7.47 billion to RMB 7.66 billion, representing 16%-19% YoY growth. Attributable net profit is forecast at RMB 729 million to RMB 772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884 million to RMB 922 million, up 17%-22% YoY. The company attributed the growth to deepening global expansion, with newly signed orders rising over 30% YoY, including small-molecule CDMO orders surging over 50%. Based on mid-range estimates, Q2 revenue grew 19.38% YoY with profitability accelerating sequentially, as Q2 net profit is projected at RMB 394-436 million versus Q1's RMB 335 million, implying 17%-30% QoQ growth.</p><p>Notably, Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovering global biopharma funding and strong outsourcing demand.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 5.59% in Regular Trading, H1 Revenue Forecast Up 16%-19% YoY with New Orders Surging Over 30%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 5.59% in Regular Trading, H1 Revenue Forecast Up 16%-19% YoY with New Orders Surging Over 30%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 10:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on July 13.</p><p>Pharmaron expects H1 revenue of RMB 7.47 billion to RMB 7.66 billion, representing 16%-19% YoY growth. Attributable net profit is forecast at RMB 729 million to RMB 772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884 million to RMB 922 million, up 17%-22% YoY. The company attributed the growth to deepening global expansion, with newly signed orders rising over 30% YoY, including small-molecule CDMO orders surging over 50%. Based on mid-range estimates, Q2 revenue grew 19.38% YoY with profitability accelerating sequentially, as Q2 net profit is projected at RMB 394-436 million versus Q1's RMB 335 million, implying 17%-30% QoQ growth.</p><p>Notably, Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovering global biopharma funding and strong outsourcing demand.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1152859766","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152859766","pubTimestamp":1783997272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨5.59%，上半年营收预计同比增长16%-19%，新订单飙升超30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On July 14, Pharmaron (03759.HK) rose 5.59% in regular trading, trading at HK$23.44/share, with turnover of HK$217 million. The rally was driven by the company's H1 earnings forecast disclosed on July 13.Pharmaron expects H1 revenue of RMB 7.47 billion to RMB 7.66 billion, representing 16%-19% YoY growth. Attributable net profit is forecast at RMB 729 million to RMB 772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884 million to RMB 922 million, up 17%-22% YoY. The company attributed the growth to deepening global expansion, with newly signed orders rising over 30% YoY, including small-molecule CDMO orders surging over 50%. Based on mid-range estimates, Q2 revenue grew 19.38% YoY with profitability accelerating sequentially, as Q2 net profit is projected at RMB 394-436 million versus Q1's RMB 335 million, implying 17%-30% QoQ growth.Notably, Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovering global biopharma funding and strong outsourcing demand.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152859766","isCrawlerRequest":true}